Pressure-induced localized lipoatrophy

Summary

Pressure-induced localized lipoatrophy (MONDO:0019556) is a disease. A subtype of localized lipodystrophy — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Phenotypes (HPO): 7

Clinical features

Signs & symptoms

Clinical features (HPO)

7 HPO clinical features (Orphanet curated; top 7 by frequency):

HPO ID	Term	Frequency
HP:0100578	Lipoatrophy	Obligate (100%)
HP:0003758	Reduced subcutaneous adipose tissue	Very frequent (80-99%)
HP:0011356	Regional abnormality of skin	Very frequent (80-99%)
HP:0007485	Absence of subcutaneous fat	Frequent (30-79%)
HP:0010783	Erythema	Frequent (30-79%)
HP:0011123	Inflammatory abnormality of the skin	Frequent (30-79%)
HP:0200036	Skin nodule	Frequent (30-79%)

Identifiers

Disease identifiers

Field	Value
Canonical name	pressure-induced localized lipoatrophy
Mondo ID	MONDO:0019556
Orphanet	90160
SNOMED CT	238898001
UMLS	C1260961
MedGen	687584
GARD	0019129
Is cancer (heuristic)	no

Also known as: lipoatrophia semicircularis · semicircular lipoatrophy

Disease family

This is a subtype of localized lipodystrophy. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by developmental or physiological process › metabolic disease › lipodystrophy › localized lipodystrophy › pressure-induced localized lipoatrophy

Related subtypes (4): centrifugal lipodystrophy, drug-induced localized lipodystrophy, idiopathic localized lipodystrophy, panniculitis and localized lipodystrophy

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 0.